Psoriasis
Conditions
Keywords
Vehicle- controlled, GSK2981278, Plaque psoriasis
Brief summary
GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR) gamma. The aim of this study is to evaluate the safety, tolerability, clinical effect, and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis by treating all plaques on the body for 8 weeks. This single-center study will be conducted in two parts. Part A will be an open-label, single arm study and part B will be a double-blind, randomized, 2-arm, parallel-group, vehicle-controlled study. In Part A, 8 adult subjects and in Part B, 18 adult subjects with chronic stable plaque psoriasis will be enrolled. Total duration of study will be approximately 14 weeks. The results of this study will provide preliminary information about safety and efficacy of the drug and will help in providing the guidance for further development strategy.
Interventions
DRUGGSK2981278 ointment
GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe. GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas .
DRUGVehicle ointment
It will be supplied as white to off-white vehicle ointment for topical application.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age and above, at the time of signing the informed consent. * Subjects with clinical diagnosis of stable plaque psoriasis for more than or equal to 6 months, as confirmed by the investigator. * BSA involvement more than or equal to 5 percent and less than or equal to 15 percent, excluding face and intertriginous areas, at Screening and Baseline. The area of psoriasis involvement may include up to 2 percent of total BSA on the scalp with only sparse terminal hair and/or vellus hair. * A PGA score of greater than or equal to 2 at Baseline. * One target plaque located on the trunk or proximal parts of extremities (excluding scalp, knees, and elbows) that is at least 9 Centimeter \^2 in size at Screening and Baseline with a TPSS greater than or equal to 5 and induration sub score greater than or equal to 2. * Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until 2 weeks after the last dose of study medication: a) Vasectomy with documentation of azoospermia. The documentation on male sterility can come from the site personnel's: review of subject's medical records, medical examination and/or semen analysis, or medical history interview. B) Male condom. The allowed method of contraception is only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. * Female of non-reproductive potential (FNRP) is eligible to participate in this study if she meets at least one of the following conditions: a) Females with one of the following procedures documented and no plans to utilize assisted reproductive techniques (e.g., in vitro fertilization or donor embryo transfer): bilateral tubal ligation or salpingectomy, hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy, bilateral Oophorectomy (surgical menopause); b) Post-menopausal women including Females 60 years of age or older, A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile, e.g., age appropriate, more than 45 years, in the absence of hormone replacement therapy (HRT) or medical suppression of the menstrual cycle (e.g., leuprolide treatment). In questionable cases for women less than 60 years of age, a blood sample with simultaneous follicle stimulating hormone and estradiol falling into the central laboratory's post-menopausal reference range is confirmatory (these levels need to be adjusted for specific laboratories/assays. Females fewer than 60 years of age, who are on HRT and wish to continue, and whose menopausal status is in doubt, should not be enrolled in this study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can enroll into the study and resume use of HRT. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
Exclusion criteria
* Psoriasis other than plaque variant (i.e. acute psoriasis guttate, psoriasis punctata, psoriasis erythroderma or pustular psoriasis). * Current evidence of another ongoing or any acute cutaneous infection, history of repeated or chronic significant skin infections (unless irrelevant in the opinion of the investigator, i.e. onychomycosis, labial herpes or other minor diagnosis). * Clinically-relevant skin disease or other skin pathologies, that may, in the opinion of the investigator, contraindicate participation or interfere with skin evaluations. * ALT more than 2x Upper limit of normal (ULN) and bilirubin more than 1.5x ULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35 percent). * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * Corrected QT interval using Bazett's formula (QTcB) more than 450 milliseconds (msec) or QTcB more than 480 msec in subjects with Bundle Branch Block. The QTcB should be based on single QTcB values of ECG obtained over a brief recording period. If QTcB is outside the threshold value, triplicate ECGs may be performed with the QTcB values averaged. * Any condition that, in the judgment of the investigator, would put the subject at un-acceptable risk for the participation in the trial. * History of malignancy within 5 years prior to dosing, except adequately treated non-invasive cancer of the skin (basal or squamous cell). * Use of prohibited concomitant medications or products within the defined periods before the Day 1 visit and during the trial * History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. * Symptoms of a clinically significant illness that may, in the opinion of the investigator, influence the outcome of the trial in the 4 weeks before baseline visit and during the trial. * Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. * A positive pre-study drug/alcohol screen. * A positive test for human immunodeficiency virus (HIV) antibody. * For Part B only-the subject has participated in Part A of this study. * The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 4 weeks, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). * Prolonged exposure to natural or artificial sources of ultraviolet (UV) radiation (e.g., exposure to sunlight other than that associated with usual daily activities, use of tanning booth, etc.) within 2 weeks prior to the Day 1 visit or intention to have such exposure during the study, thought by the investigator likely to modify the subject's psoriasis. * In the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical trial, e.g. due to probable noncompliance, inability to understand the trial and give adequately informed consent, or inability to complete the Psoriasis Symptom Diary. * Close affiliation with the investigator (e.g. a close relative) or persons working at bioskin GmbH or subject is an employee of sponsor. * Subject is institutionalized because of legal or regulatory order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Percent Change in PASI From Baseline to Week 8: Part B | Baseline and up to Week 8 | The PASI is a standard tool for assessing the severity of psoriasis that considers the overall severity of erythema, thickness, and scale, and the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0=none to 4=severe) and the percent BSA affected is scored on a 7-point scale (0= 0% skin with psoriasis to 6=\>=90% skin with psoriasis). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. Last observation values collected were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With Abnormal Findings for ECG Parameters: Part B | Up to Day 57 | Single measurements of 12-lead ECGs were planned to be obtained using an ECG machine. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Mean Percent Change in TPSS From Baseline to Week 8: Part B | Baseline and up to Week 8 | The TPSS is the measure of clinical effect of GSK2981278. TPSS Total score was calculated by adding the individual scores of erythema, scaling, and induration (plaque thickness), assessed by the investigator on a 5-point scale ranging from 0=none to 4=very marked. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Mean Percent Change in PGA Score From Baseline to Week 8: Part B | Baseline and up to Week 8 | The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. The 5-point scale ranges from 0=clear to 4=severe. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as by subtracting post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A | Up to Day 57 | An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. The analysis was performed on Safety analysis Population which comprised of all participants exposed to at least 1 application of study medication. |
| Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1, Day 15, Day 29, Day 57 | The investigator assessed application site tolerability focusing on the treated non-lesional skin surrounding the plaques at each visit using the 5-point tolerability assessment scale ranging from 0 (no intolerance) to 4 (very severe intolerance). Number of participants in the corresponding score at Day 1, 15, 29 and 57 has been presented. |
| Number of Participants With Negative Urinalysis Results: Part A | Up to Day 57 | Urine samples were collected from participants to evaluate urinalysis parameters including glucose, protein, erythrocytes and ketones. Number of participants with negative or normal urinalysis results at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. |
| Change From Baseline in Potential of Hydrogen (pH) of Urine: Part A | Baseline and up to Day 57 | The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. Urine samples were collected from participants and urine pH levels were assessed at Baseline, Day 15, Day 29 and Day 57. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Specific Gravity of Urine: Part A | Baseline and up to Day 57 | Urine samples were collected from participants and specific gravity levels were assessed at Baseline, Day 15, Day 29 and Day 57. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical chemistry parameters including BUN, glucose, potassium, sodium and calcium. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine, total and direct bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical chemistry parameters including AST, ALT and alkaline phosphatase. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Protein and Albumin Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical chemistry parameters including protein and albumin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including platelets, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Erythrocyte Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocytes. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Hemoglobin Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Hematocrit Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Mean Corpuscular Volume (MCV) Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels: Part A | Baseline and up to Day 57 | Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | Baseline and up to Day 57 | Vital sign measurements including SBP and DBP were taken in a seated or supine position after 5-minutes of rest. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Pulse Rate Levels: Part A | Baseline and up to Day 57 | Vital sign measurements including pulse rate were taken in a seated or supine position after 5-minutes of rest. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. |
| Change From Baseline in Electrocardiogram (ECG) Parameters Including Single RR Heart Rate: Part A | Baseline and up to Day 57 | Single measurements of 12-lead ECG were obtained using an ECG machine to measure RR heart rate. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value |
| Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | Baseline and up to Day 57 | Single measurements of 12-lead ECG were obtained using an ECG machine to measure PR interval, QRS duration, QT interval, QTcB and RR interval. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value |
| Plasma Concentration of GSK2981278 at Nominal Time: Part A | Pre-dose, 1, 2, 4, 6, 8, 10 hours post-dose on Day 1, Day 29 and Day 57; Pre-dose, 2 hours post-dose on Day 15 | Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2981278. Non-quantifiable values in a profile occurring before the first measurable concentration were assigned a value of zero concentration. Single non-quantifiable values occurring between measurable concentrations in a profile were omitted. The analysis was performed on PK analysis Population which comprised of participants with at least one sample collected and analyzed for plasma drug concentration. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). |
| Number of Participants With SAEs and Non-SAEs: Part B | Up to Day 57 | An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. The analysis was performed on Safety analysis set Population which comprised of all participants exposed to at least 1 application of study medication. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part B | Up to Day 57 | The investigator planned to assess application site tolerability focusing on the treated non-lesional skin surrounding the plaques at each visit using the 5-point tolerability assessment scale ranging from 0 (no intolerance) to 4 (very severe intolerance). Number of participants with Application site tolerability assessment score were planned to be analyzed. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With Change in Clinical Chemistry Toxicity Grade From Baseline: Part B | Baseline and up to Week 57 | Blood samples were planned to be collected for evaluation of clinical chemistry parameters. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as by subtracting post-Baseline visit values minus Baseline value. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With Change in Hematology Toxicity Grade From Baseline: Part B | Baseline and up to Day 57 | Blood samples were planned to be collected for the analysis of hematology parameters. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
| Number of Participants With Critical Changes in Values of Vital Signs in Response to Drug: Part B | Up to Day 57 | Vital sign measurement includes SBP, DBP, temperature, pulse rate. This analysis was planned but not performed for Part B as the study was terminated during Part A. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Percent Change From Baseline in Physician's Global Assessment (PGA) Score: Part A | Baseline and up to Week 8 | The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. The 5-point scale ranges from 0=clear to 4=severe. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100. |
| Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score: Part A | Baseline and up to Week 8 | The PASI is a standard tool for assessing the severity of psoriasis that considers the overall severity of erythema, thickness, and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0=none to 4=severe) and the percent BSA affected is scored on a 7-point scale (0= 0% skin with psoriasis to 6=\>=90% skin with psoriasis) for each of the 4 specified body regions. The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100. |
| Mean Percent Change From Baseline in Target Plaque Severity Score (TPSS): Part A | Baseline and up to Week 8 | The TPSS is the measure of clinical effect of GSK2981278. A target lesion of at least 9 centimeter square (cm\^2) with a TPSS \>=5 and an induration sub score \>=2 was selected at Baseline. TPSS Total score was calculated by adding the individual scores of erythema, scaling, and induration (plaque thickness), assessed by the investigator on a 5-point scale ranging from 0=none to 4=very marked. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100. The analysis was performed on per protocol (PP) analysis Population which comprised of all participants eligible for treatment phase and who comply closely with the protocol. |
Countries
Germany
Participant flow
Recruitment details
Participants with chronic stable plaque psoriasis were recruited in this 2 part study to evaluate safety, tolerability and clinical effect of GSK2981278.
Pre-assignment details
A total of 10 participants were screened; of which two were screen failures and eight were included in the treatment phase of Part A and received GSK2981278 4% ointment for 8 weeks. Part B of this study was not conducted as pre-defined efficacy criteria for continuing to Part B were not met. Hence no participants were enrolled in Part B.
Participants by arm
| Arm | Count |
|---|---|
| GSK2981278 4%: Part A Participants received 4% ointment of GSK2981278 twice daily for 8 weeks. | 8 |
| GSK2981278 4%: Part B Randomized participants were planned to receive 4% ointment of GSK2981278 twice daily for 8 weeks. | 0 |
| Vehicle Ointment: Part B Randomized participants were planned to receive vehicle ointment twice daily for 8 weeks. | 0 |
| Total | 8 |
Baseline characteristics
| Characteristic | GSK2981278 4%: Part A | Total |
|---|---|---|
| Age, Continuous | 54.9 Years STANDARD_DEVIATION 9.43 | 54.9 Years STANDARD_DEVIATION 9.43 |
| Race/Ethnicity, Customized White - White/Caucasian/European heritage | 8 Participants | 8 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 8 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 1 / 8 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 8 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A
Blood samples were collected from participants to evaluate clinical chemistry parameters including AST, ALT and alkaline phosphatase. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | AST; Day 15 | 1.3 International unit per liter (IU/L) | Standard Deviation 4.43 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | AST; Day 29 | -0.3 International unit per liter (IU/L) | Standard Deviation 2.92 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | AST; Day 57 | -0.3 International unit per liter (IU/L) | Standard Deviation 6.23 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | ALT; Day 15 | 2.8 International unit per liter (IU/L) | Standard Deviation 8.75 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | ALT; Day 29 | 0.6 International unit per liter (IU/L) | Standard Deviation 5.26 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | ALT; Day 57 | 2.0 International unit per liter (IU/L) | Standard Deviation 8.59 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | Alkaline phosphatase; Day 15 | 2.1 International unit per liter (IU/L) | Standard Deviation 5.87 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | Alkaline phosphatase; Day 29 | 2.9 International unit per liter (IU/L) | Standard Deviation 12.89 |
| GSK2981278 4%: Part A | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase Levels: Part A | Alkaline phosphatase; Day 57 | -0.8 International unit per liter (IU/L) | Standard Deviation 11.8 |
Primary
Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A
Blood samples were collected from participants to evaluate clinical chemistry parameters including BUN, glucose, potassium, sodium and calcium. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | BUN; Day 15 | -0.2678 Millimoles per liter (Mmol/L) | Standard Deviation 1.233 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | BUN; Day 29 | -0.3570 Millimoles per liter (Mmol/L) | Standard Deviation 0.4267 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | BUN; Day 57 | 0.4909 Millimoles per liter (Mmol/L) | Standard Deviation 1.40146 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Glucose; Day 15 | 0.041632 Millimoles per liter (Mmol/L) | Standard Deviation 0.7296677 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Glucose; Day 29 | 0.104081 Millimoles per liter (Mmol/L) | Standard Deviation 0.7258495 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Glucose; Day 57 | 0.298366 Millimoles per liter (Mmol/L) | Standard Deviation 0.4163911 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Potassium; Day 15 | -0.14 Millimoles per liter (Mmol/L) | Standard Deviation 0.272 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Potassium; Day 29 | 0.00 Millimoles per liter (Mmol/L) | Standard Deviation 0.312 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Potassium; Day 57 | 0.13 Millimoles per liter (Mmol/L) | Standard Deviation 0.328 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Sodium; Day 15 | -1.1 Millimoles per liter (Mmol/L) | Standard Deviation 2.17 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Sodium; Day 29 | 0.8 Millimoles per liter (Mmol/L) | Standard Deviation 2.25 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Sodium; Day 57 | -0.4 Millimoles per liter (Mmol/L) | Standard Deviation 1.06 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Calcium; Day 15 | 0.021 Millimoles per liter (Mmol/L) | Standard Deviation 0.0624 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Calcium; Day 29 | 0.038 Millimoles per liter (Mmol/L) | Standard Deviation 0.0765 |
| GSK2981278 4%: Part A | Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Potassium, Sodium and Calcium Levels: Part A | Calcium; Day 57 | -0.013 Millimoles per liter (Mmol/L) | Standard Deviation 0.0886 |
Primary
Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A
Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine, total and direct bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Creatinine; Day 15 | -5.8565 Micromoles per liter (µmol/L) | Standard Deviation 2.16212 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Creatinine; Day 29 | -3.8675 Micromoles per liter (µmol/L) | Standard Deviation 6.32075 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Creatinine; Day 57 | -3.7570 Micromoles per liter (µmol/L) | Standard Deviation 6.92444 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Total bilirubin; Day 15 | 1.425 Micromoles per liter (µmol/L) | Standard Deviation 2.7396 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Total bilirubin; Day 29 | 1.995 Micromoles per liter (µmol/L) | Standard Deviation 2.5171 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Total bilirubin; Day 57 | -0.342 Micromoles per liter (µmol/L) | Standard Deviation 1.4307 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Direct bilirubin; Day 15 | 0.3705 Micromoles per liter (µmol/L) | Standard Deviation 0.66154 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Direct bilirubin; Day 29 | 0.3990 Micromoles per liter (µmol/L) | Standard Deviation 0.79963 |
| GSK2981278 4%: Part A | Change From Baseline in Creatinine, Total and Direct Bilirubin Levels: Part A | Direct bilirubin; Day 57 | 0.0000 Micromoles per liter (µmol/L) | Standard Deviation 0.52706 |
Primary
Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A
Single measurements of 12-lead ECG were obtained using an ECG machine to measure PR interval, QRS duration, QT interval, QTcB and RR interval. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | PR interval; Day 29 | -0.5 Milliseconds (msec) | Standard Deviation 9.78 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | PR interval; Day 57 | 7.3 Milliseconds (msec) | Standard Deviation 12.78 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QRS duration; Day 29 | -0.5 Milliseconds (msec) | Standard Deviation 4.24 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QRS duration; Day 57 | -0.3 Milliseconds (msec) | Standard Deviation 2.92 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QT interval; Day 29 | 12.8 Milliseconds (msec) | Standard Deviation 28.88 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QT interval; Day 57 | 9.0 Milliseconds (msec) | Standard Deviation 28.57 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QTcB interval; Day 29 | 10.0 Milliseconds (msec) | Standard Deviation 15.62 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | QTcB interval; Day 57 | 3.5 Milliseconds (msec) | Standard Deviation 15.96 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | RR interval; Day 29 | 9.5 Milliseconds (msec) | Standard Deviation 170.62 |
| GSK2981278 4%: Part A | Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and RR Interval: Part A | RR interval; Day 57 | 13.0 Milliseconds (msec) | Standard Deviation 124.12 |
Primary
Change From Baseline in Electrocardiogram (ECG) Parameters Including Single RR Heart Rate: Part A
Single measurements of 12-lead ECG were obtained using an ECG machine to measure RR heart rate. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Electrocardiogram (ECG) Parameters Including Single RR Heart Rate: Part A | Day 29 | -2.5 Beats per minute | Standard Deviation 16.81 |
| GSK2981278 4%: Part A | Change From Baseline in Electrocardiogram (ECG) Parameters Including Single RR Heart Rate: Part A | Day 57 | -3.5 Beats per minute | Standard Deviation 12.42 |
Primary
Change From Baseline in Erythrocyte Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocytes. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Erythrocyte Levels: Part A | Day 15 | 0.013 10^12 cells/L | Standard Deviation 0.2042 |
| GSK2981278 4%: Part A | Change From Baseline in Erythrocyte Levels: Part A | Day 29 | 0.055 10^12 cells/L | Standard Deviation 0.2555 |
| GSK2981278 4%: Part A | Change From Baseline in Erythrocyte Levels: Part A | Day 57 | 0.061 10^12 cells/L | Standard Deviation 0.2785 |
Primary
Change From Baseline in Hematocrit Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Hematocrit Levels: Part A | Day 15 | 0.0040 Proportion of Red blood cells in blood | Standard Deviation 0.01752 |
| GSK2981278 4%: Part A | Change From Baseline in Hematocrit Levels: Part A | Day 29 | 0.0090 Proportion of Red blood cells in blood | Standard Deviation 0.02203 |
| GSK2981278 4%: Part A | Change From Baseline in Hematocrit Levels: Part A | Day 57 | 0.0076 Proportion of Red blood cells in blood | Standard Deviation 0.02628 |
Primary
Change From Baseline in Hemoglobin Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Hemoglobin Levels: Part A | Day 15 | 1.3 g/L | Standard Deviation 6.18 |
| GSK2981278 4%: Part A | Change From Baseline in Hemoglobin Levels: Part A | Day 29 | 2.6 g/L | Standard Deviation 7.63 |
| GSK2981278 4%: Part A | Change From Baseline in Hemoglobin Levels: Part A | Day 57 | 1.5 g/L | Standard Deviation 9.18 |
Primary
Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels: Part A | Day 15 | 0.16 Picograms (Pg) | Standard Deviation 0.325 |
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels: Part A | Day 29 | 0.21 Picograms (Pg) | Standard Deviation 0.253 |
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels: Part A | Day 57 | -0.06 Picograms (Pg) | Standard Deviation 0.421 |
Primary
Change From Baseline in Mean Corpuscular Volume (MCV) Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Volume (MCV) Levels: Part A | Day 15 | 0.46 Femtoliter (fL) | Standard Deviation 1.235 |
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Volume (MCV) Levels: Part A | Day 29 | 0.86 Femtoliter (fL) | Standard Deviation 1.112 |
| GSK2981278 4%: Part A | Change From Baseline in Mean Corpuscular Volume (MCV) Levels: Part A | Day 57 | 0.34 Femtoliter (fL) | Standard Deviation 1.172 |
Primary
Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A
Blood samples were collected from participants to evaluate clinical hematology parameters including platelets, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Change from Baseline in clinical hematology parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Platelet; Day 15 | -3.6 10^9 cells/L | Standard Deviation 50.9 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Platelet; Day 29 | -1.0 10^9 cells/L | Standard Deviation 28.98 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Platelet; Day 57 | 0.1 10^9 cells/L | Standard Deviation 25.31 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Leukocytes; Day 15 | 0.76 10^9 cells/L | Standard Deviation 2.745 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Leukocytes; Day 29 | 0.42 10^9 cells/L | Standard Deviation 0.91 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Leukocytes; Day 57 | 0.35 10^9 cells/L | Standard Deviation 0.78 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Neutrophils; Day 15 | 0.695 10^9 cells/L | Standard Deviation 2.7477 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Neutrophils; Day 29 | 0.144 10^9 cells/L | Standard Deviation 1.1659 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Neutrophils; Day 57 | 0.217 10^9 cells/L | Standard Deviation 0.4432 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Lymphocytes; Day 15 | -0.019 10^9 cells/L | Standard Deviation 0.6335 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Lymphocytes; Day 29 | 0.243 10^9 cells/L | Standard Deviation 0.4457 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Lymphocytes; Day 57 | 0.151 10^9 cells/L | Standard Deviation 0.3756 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Monocytes; Day 15 | 0.090 10^9 cells/L | Standard Deviation 0.2778 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Monocytes; Day 29 | -0.040 10^9 cells/L | Standard Deviation 0.2099 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Monocytes; Day 57 | -0.063 10^9 cells/L | Standard Deviation 0.2344 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Eosinophils; Day 15 | 0.019 10^9 cells/L | Standard Deviation 0.1579 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Eosinophils; Day 29 | 0.085 10^9 cells/L | Standard Deviation 0.1321 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Eosinophils; Day 57 | 0.029 10^9 cells/L | Standard Deviation 0.0825 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Basophils; Day 15 | -0.008 10^9 cells/L | Standard Deviation 0.0287 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Basophils; Day 29 | 0.001 10^9 cells/L | Standard Deviation 0.0264 |
| GSK2981278 4%: Part A | Change From Baseline in Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils Levels: Part A | Basophils; Day 57 | 0.004 10^9 cells/L | Standard Deviation 0.0151 |
Primary
Change From Baseline in Potential of Hydrogen (pH) of Urine: Part A
The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. Urine samples were collected from participants and urine pH levels were assessed at Baseline, Day 15, Day 29 and Day 57. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Potential of Hydrogen (pH) of Urine: Part A | Day 15 | 0.1 Scores on a scale | Standard Deviation 0.83 |
| GSK2981278 4%: Part A | Change From Baseline in Potential of Hydrogen (pH) of Urine: Part A | Day 29 | -0.1 Scores on a scale | Standard Deviation 0.35 |
| GSK2981278 4%: Part A | Change From Baseline in Potential of Hydrogen (pH) of Urine: Part A | Day 57 | -0.1 Scores on a scale | Standard Deviation 0.35 |
Primary
Change From Baseline in Protein and Albumin Levels: Part A
Blood samples were collected from participants to evaluate clinical chemistry parameters including protein and albumin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Protein; Day 15 | 1.9 Grams per liter (g/L) | Standard Deviation 2.9 |
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Protein; Day 29 | -1.4 Grams per liter (g/L) | Standard Deviation 2.83 |
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Protein; Day 57 | 1.8 Grams per liter (g/L) | Standard Deviation 3.65 |
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Albumin; Day 15 | 1.4 Grams per liter (g/L) | Standard Deviation 1.92 |
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Albumin; Day 29 | 1.3 Grams per liter (g/L) | Standard Deviation 1.67 |
| GSK2981278 4%: Part A | Change From Baseline in Protein and Albumin Levels: Part A | Albumin; Day 57 | 1.0 Grams per liter (g/L) | Standard Deviation 2.56 |
Primary
Change From Baseline in Pulse Rate Levels: Part A
Vital sign measurements including pulse rate were taken in a seated or supine position after 5-minutes of rest. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Pulse Rate Levels: Part A | Day 15 | 3.3 Beats per minute | Standard Deviation 9.19 |
| GSK2981278 4%: Part A | Change From Baseline in Pulse Rate Levels: Part A | Day 29 | 0.3 Beats per minute | Standard Deviation 12.21 |
| GSK2981278 4%: Part A | Change From Baseline in Pulse Rate Levels: Part A | Day 57 | 1.3 Beats per minute | Standard Deviation 11.36 |
Primary
Change From Baseline in Specific Gravity of Urine: Part A
Urine samples were collected from participants and specific gravity levels were assessed at Baseline, Day 15, Day 29 and Day 57. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Specific Gravity of Urine: Part A | Day 15 | 0.0019 Ratio | Standard Deviation 0.00799 |
| GSK2981278 4%: Part A | Change From Baseline in Specific Gravity of Urine: Part A | Day 29 | 0.0019 Ratio | Standard Deviation 0.0053 |
| GSK2981278 4%: Part A | Change From Baseline in Specific Gravity of Urine: Part A | Day 57 | 0.0025 Ratio | Standard Deviation 0.00707 |
Primary
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A
Vital sign measurements including SBP and DBP were taken in a seated or supine position after 5-minutes of rest. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | SBP; Day 15 | -1.9 Millimeters of mercury (mmHg) | Standard Deviation 4.58 |
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | SBP; Day 29 | -2.5 Millimeters of mercury (mmHg) | Standard Deviation 4.63 |
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | SBP; Day 57 | -2.5 Millimeters of mercury (mmHg) | Standard Deviation 2.67 |
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | DBP; Day 15 | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 2.67 |
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | DBP; Day 29 | 1.3 Millimeters of mercury (mmHg) | Standard Deviation 4.43 |
| GSK2981278 4%: Part A | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels: Part A | DBP: Day 57 | 0.6 Millimeters of mercury (mmHg) | Standard Deviation 4.17 |
Primary
Mean Percent Change in PASI From Baseline to Week 8: Part B
The PASI is a standard tool for assessing the severity of psoriasis that considers the overall severity of erythema, thickness, and scale, and the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0=none to 4=severe) and the percent BSA affected is scored on a 7-point scale (0= 0% skin with psoriasis to 6=\>=90% skin with psoriasis). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. Last observation values collected were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Baseline and up to Week 8
Population: PP analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Mean Percent Change in PGA Score From Baseline to Week 8: Part B
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. The 5-point scale ranges from 0=clear to 4=severe. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as by subtracting post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Baseline and up to Week 8
Population: PP analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Mean Percent Change in TPSS From Baseline to Week 8: Part B
The TPSS is the measure of clinical effect of GSK2981278. TPSS Total score was calculated by adding the individual scores of erythema, scaling, and induration (plaque thickness), assessed by the investigator on a 5-point scale ranging from 0=none to 4=very marked. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Baseline and up to Week 8
Population: PP analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Abnormal Findings for ECG Parameters: Part B
Single measurements of 12-lead ECGs were planned to be obtained using an ECG machine. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Up to Day 57
Population: Safety analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A
The investigator assessed application site tolerability focusing on the treated non-lesional skin surrounding the plaques at each visit using the 5-point tolerability assessment scale ranging from 0 (no intolerance) to 4 (very severe intolerance). Number of participants in the corresponding score at Day 1, 15, 29 and 57 has been presented.
Time frame: Day 1, Day 15, Day 29, Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1; Grade 0 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1; Grade 1 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1; Grade 2 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1; Grade 3 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 1; Grade 4 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 15; Grade 0 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 15; Grade 1 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 15; Grade 2 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 15; Grade 3 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 15; Grade 4 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 29; Grade 0 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 29; Grade 1 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 29; Grade 2 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 29; Grade 3 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 29; Grade 4 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 57; Grade 0 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 57; Grade 1 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 57; Grade 2 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 57; Grade 3 | 0 Participants |
| GSK2981278 4%: Part A | Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part A | Day 57; Grade 4 | 0 Participants |
Primary
Number of Participants With Application Site Tolerability Assessment Score During Treatment Period: Part B
The investigator planned to assess application site tolerability focusing on the treated non-lesional skin surrounding the plaques at each visit using the 5-point tolerability assessment scale ranging from 0 (no intolerance) to 4 (very severe intolerance). Number of participants with Application site tolerability assessment score were planned to be analyzed. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Up to Day 57
Population: Safety analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Change in Clinical Chemistry Toxicity Grade From Baseline: Part B
Blood samples were planned to be collected for evaluation of clinical chemistry parameters. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as by subtracting post-Baseline visit values minus Baseline value. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Baseline and up to Week 57
Population: Safety analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Change in Hematology Toxicity Grade From Baseline: Part B
Blood samples were planned to be collected for the analysis of hematology parameters. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Baseline and up to Day 57
Population: Safety analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Critical Changes in Values of Vital Signs in Response to Drug: Part B
Vital sign measurement includes SBP, DBP, temperature, pulse rate. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Up to Day 57
Population: Safety analysis Population. Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Number of Participants With Negative Urinalysis Results: Part A
Urine samples were collected from participants to evaluate urinalysis parameters including glucose, protein, erythrocytes and ketones. Number of participants with negative or normal urinalysis results at Day 15, Day 29 and Day 57 are presented. Last observation values collected prior to the first application of study treatment were considered as Baseline values.
Time frame: Up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Glucose; Baseline | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Glucose; Day 15 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Glucose; Day 29 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Glucose; Day 57 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Protein; Baseline | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Protein; Day 15 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Protein; Day 29 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Protein; Day 57 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Erythrocytes; Baseline | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Erythrocytes; Day 15 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Erythrocytes; Day 29 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Erythrocytes; Day 57 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Ketones; Baseline | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Ketones; Day 15 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Ketones; Day 29 | 8 Participants |
| GSK2981278 4%: Part A | Number of Participants With Negative Urinalysis Results: Part A | Ketones; Day 57 | 8 Participants |
Primary
Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. The analysis was performed on Safety analysis Population which comprised of all participants exposed to at least 1 application of study medication.
Time frame: Up to Day 57
Population: Safety analysis Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2981278 4%: Part A | Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A | non-SAEs | 1 Participants |
| GSK2981278 4%: Part A | Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A | SAEs | 0 Participants |
Primary
Number of Participants With SAEs and Non-SAEs: Part B
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. The analysis was performed on Safety analysis set Population which comprised of all participants exposed to at least 1 application of study medication. This analysis was planned but not performed for Part B as the study was terminated during Part A.
Time frame: Up to Day 57
Population: Safety analysis population. . Data was not collected for Part B as no Participants were enrolled into this part of the study.
Primary
Plasma Concentration of GSK2981278 at Nominal Time: Part A
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2981278. Non-quantifiable values in a profile occurring before the first measurable concentration were assigned a value of zero concentration. Single non-quantifiable values occurring between measurable concentrations in a profile were omitted. The analysis was performed on PK analysis Population which comprised of participants with at least one sample collected and analyzed for plasma drug concentration. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose, 1, 2, 4, 6, 8, 10 hours post-dose on Day 1, Day 29 and Day 57; Pre-dose, 2 hours post-dose on Day 15
Population: PK analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | Pre-dose; Day 1; n= 8 | 0.00 Picograms per milliliter (Pg/mL) | Standard Deviation 0 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 1 hour post-dose; Day 1; n= 8 | 151.89 Picograms per milliliter (Pg/mL) | Standard Deviation 210.535 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 2 hours post-dose; Day 1; n= 8 | 281.54 Picograms per milliliter (Pg/mL) | Standard Deviation 589.927 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 4 hours post-dose; Day 1; n= 8 | 171.38 Picograms per milliliter (Pg/mL) | Standard Deviation 160.357 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 6 hours post-dose; Day 1; n= 8 | 610.73 Picograms per milliliter (Pg/mL) | Standard Deviation 1141.415 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 8 hours post-dose; Day 1; n= 8 | 192.06 Picograms per milliliter (Pg/mL) | Standard Deviation 168.443 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 10 hours post-dose; Day 1; n= 8 | 554.94 Picograms per milliliter (Pg/mL) | Standard Deviation 828.825 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | Pre-dose; Day 15; n= 7 | 1203.71 Picograms per milliliter (Pg/mL) | Standard Deviation 1203.796 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 2 hours post-dose; Day 15; n= 8 | 893.00 Picograms per milliliter (Pg/mL) | Standard Deviation 737.61 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | Pre-dose; Day 29; n= 8 | 1122.00 Picograms per milliliter (Pg/mL) | Standard Deviation 587.76 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 1 hour post-dose; Day 29; n= 8 | 1299.63 Picograms per milliliter (Pg/mL) | Standard Deviation 910.793 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 2 hours post-dose; Day 29; n= 8 | 1062.38 Picograms per milliliter (Pg/mL) | Standard Deviation 662.05 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 4 hours post-dose; Day 29; n= 8 | 769.38 Picograms per milliliter (Pg/mL) | Standard Deviation 369.861 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 6 hours post-dose; Day 29; n= 8 | 1022.63 Picograms per milliliter (Pg/mL) | Standard Deviation 720.269 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 8 hours post-dose; Day 29; n= 7 | 897.71 Picograms per milliliter (Pg/mL) | Standard Deviation 325.169 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 10 hours post-dose; Day 29; n= 8 | 875.38 Picograms per milliliter (Pg/mL) | Standard Deviation 584.879 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | Pre-dose; Day 57; n= 8 | 875.75 Picograms per milliliter (Pg/mL) | Standard Deviation 707.446 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 1 hour post-dose; Day 57; n= 8 | 1273.75 Picograms per milliliter (Pg/mL) | Standard Deviation 784.902 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 2 hours post-dose; Day 57; n= 8 | 1077.00 Picograms per milliliter (Pg/mL) | Standard Deviation 1128.07 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 4 hours post-dose; Day 57; n= 8 | 758.13 Picograms per milliliter (Pg/mL) | Standard Deviation 494.661 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 6 hours post-dose; Day 57; n= 8 | 760.38 Picograms per milliliter (Pg/mL) | Standard Deviation 550.695 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 8 hours post-dose; Day 57; n= 8 | 809.13 Picograms per milliliter (Pg/mL) | Standard Deviation 373.947 |
| GSK2981278 4%: Part A | Plasma Concentration of GSK2981278 at Nominal Time: Part A | 10 hours post-dose; Day 57; n= 8 | 841.25 Picograms per milliliter (Pg/mL) | Standard Deviation 579.772 |
Secondary
Mean Percent Change From Baseline in Physician's Global Assessment (PGA) Score: Part A
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. The 5-point scale ranges from 0=clear to 4=severe. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from baseline value by Baseline value and multiplying it by 100.
Time frame: Baseline and up to Week 8
Population: PP analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Physician's Global Assessment (PGA) Score: Part A | Day 15 | -3.1 Percent change | Standard Deviation 8.84 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Physician's Global Assessment (PGA) Score: Part A | Day 29 | -3.1 Percent change | Standard Deviation 8.84 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Physician's Global Assessment (PGA) Score: Part A | Day 57 | 0.0 Percent change | Standard Deviation 0 |
Secondary
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score: Part A
The PASI is a standard tool for assessing the severity of psoriasis that considers the overall severity of erythema, thickness, and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0=none to 4=severe) and the percent BSA affected is scored on a 7-point scale (0= 0% skin with psoriasis to 6=\>=90% skin with psoriasis) for each of the 4 specified body regions. The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
Time frame: Baseline and up to Week 8
Population: PP analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score: Part A | Day 15 | -3.98 Percent change | Standard Deviation 10.459 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score: Part A | Day 29 | -0.27 Percent change | Standard Deviation 4.058 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score: Part A | Day 57 | 4.26 Percent change | Standard Deviation 7.119 |
Secondary
Mean Percent Change From Baseline in Target Plaque Severity Score (TPSS): Part A
The TPSS is the measure of clinical effect of GSK2981278. A target lesion of at least 9 centimeter square (cm\^2) with a TPSS \>=5 and an induration sub score \>=2 was selected at Baseline. TPSS Total score was calculated by adding the individual scores of erythema, scaling, and induration (plaque thickness), assessed by the investigator on a 5-point scale ranging from 0=none to 4=very marked. Last observation values collected prior to the first application of study treatment were considered as Baseline values. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100. The analysis was performed on per protocol (PP) analysis Population which comprised of all participants eligible for treatment phase and who comply closely with the protocol.
Time frame: Baseline and up to Week 8
Population: PP analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Target Plaque Severity Score (TPSS): Part A | Day 15 | -6.5 Percent change | Standard Deviation 7.24 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Target Plaque Severity Score (TPSS): Part A | Day 29 | -3.0 Percent change | Standard Deviation 5.74 |
| GSK2981278 4%: Part A | Mean Percent Change From Baseline in Target Plaque Severity Score (TPSS): Part A | Day 57 | -4.3 Percent change | Standard Deviation 10.61 |